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Abstract
Background: Migraine is one of the most prevalent chronic pain manifestations of childhood. Despite the
multitude of available treatments, parents are often concerned about chronic therapies and pediatricians have
insufficient confidence in prescribing prophylactic drugs. Therefore, there is now growing interest for natural
supplements used to control recurrent migraine headaches. Such approach may increase acceptance and
adherence to long-term prophylaxis therapy in children.
Methods: This is an observational multicenter study performed in children (n = 91) with migraine, with (MO) or
without aura (MA), or tension-type headache (TTH). A fixed-dose Andrographis paniculata, CoQ10, riboflavin, and
magnesium, was administered for 16 weeks. Patients were evaluated at baseline (T0), at week 8 (T1) and at the end
of treatment at week 16 (T2). A follow-up period occurred at week 20 (T3) and week 32 (T4).
Results: The herbal supplement significantly reduced the frequency of headaches in TTH patients during treatment period
(T0: 11.97 + 1.92 vs T2: 5.13 + 1.93; p< 0.001) and the efficacy was maintained after 16weeks of treatment withdrawal (T4: 4.
46 + 1.75; p< 0.001 vs T0). The frequency of migraine attacks was also reduced in the MO group during treatment (T0: 9.
70 + 0.96 vs T2: 4.03 + 0.75; p< 0.01) and after withdrawal (T4: 2.96 + 0.65; p < 0.01 vs T0). Conversely, MA patients showed
reduction in migraine’s frequency during treatment (T0: 8.74 + 1.91 vs T2: 3.78 + 2.02; p < 0.01) but not at the end of the
study (T4: 5.57 + 3.31; p> 0.05 vs T0).
TTH patients did not report significant improvement of pain intensity. A significant effect was observed in the MO group
during treatment (T0: 3.06 + 0.11 vs T2: 2.14 + 0.19; p< 0.001) and after treatment withdrawal (T4: 2.20 + 0.21; p < 0.001 vs
T0). Likewise, MA group showed a significant treatment effect (T0: 2.57 + 0.20 vs T2: 0.86 + 0.45; p < 0.001) and the efficacy
persisted at the end of the study (T4: 1.00 + 0.58; p < 0.001 vs T0).
Conclusion: This fixed-dose Tanacetum parthenium preparation improved headache frequency and pain intensity in
children affected by TTH. Despite the main limits, this study supports the use of nutraceutical in pediatric headache/
migraine.
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Background
Migraine is one of the most prevalent neurological symptom
and chronic pain manifestation of childhood, affecting up to
10% of children between the ages of 5 and 15 years and up
to 28% of adolescents aged from 15 to 19 years [1]. Migraine
is defined as an episodic pain disorder that can vary from an
occasional occurrence to a daily frequency and can subse-
quently become a very disabling disorder, with a substantial
effect on the child’s quality of life [2, 3] . The disease can
cause a significant distress as for the child, as for the entire
family. If not successfully treated, frequent and recurrent
headaches can impact families with significant disability due
to loss of school, work, and social activities. As for adults,
migraine treatment traditionally includes acute therapy for
aborting migraine attacks and prophylactic treatment for re-
ducing the frequency, duration and severity of attacks [4].
Notably, headache amongst children has a high risk of devel-
opment into a chronic condition and persisting into adult-
hood [5]. Thus, in children an effective early treatment
would be expected to impact disease progression before
many of the refractory aspects seen in adults become estab-
lished [6]. There are several classes of medications that may
be used for prophylactic therapy like antidepressants, anti-
convulsants, antihistamines, beta-adrenergic receptor
blockers, and calcium ion channel antagonists, botulinum
toxin [7, 8]. Due to the potential limitations of conventional
treatment of obtaining a satisfactory response to pain in
many cases of primary headache, various alternative treat-
ments are sought by patients; in particular, parents ask
healthcare professionals to provide migraine relief for their
children. Moreover, even clinicians prefer to avoid prescrip-
tion of prophylactic therapies in children due to the poor evi-
dence of efficacy and significant potential adverse effects in
this population [9] and the well-known “placebo effect” ob-
served in children [10].
There is now growing interest for natural supplements
for migraine and headache treatment. Due to the low
side effects, several studies support the efficacy of nat-
ural treatments, in particular nutraceuticals, in the
prophylactic treatment of migraine in children and ado-
lescents, even if the evidences are still limited [11].
Nutraceutical is a term derived from “nutrition” and
“pharmaceutical”, indicating “food, or parts of a food, that
provide medical or health benefits, including the prevention
and treatment of diseases”. Nutraceutical treatment consists
of taking vitamins, supplements (like magnesium, riboflavin,
coenzyme Q10, and alpha lipoic acid) and herbal prepara-
tions (like feverfew and butterbur). This type of approach en-
hances patient acceptance and adherence to long-term
prophylaxis therapy combined with appropriate information
on treatments’ efficacy and safety [11].
Magnesium (Mg2+) has a role in various biological
processess and it is involved in ATP production and
function and in the control of vascular tone and it binds
to NMDA receptors; its role has been suggested because
of magnesium deficiency demonstrated in headache phy-
siopathogenesis [11]. Coenzyme Q10 (CQ10) has shown
a crucial role in sustaining mitochondrial energy stores,
as a carrier in the mitochondrial electrons transport
chain; furthermore it has antioxidant proprieties. A role
of Cq10 in migraine pathogenesis has been postulated
because migraineurs have difficulties in energy produc-
tion [11]. Riboflavin (B2 vit) has two active coenzyme
forms cofactors in oxidation–reduction reaction of flavo-
proteins and seems to reduce symptoms in patients with
mitochondrial dysfunction [11]. The anti-migraine activ-
ity of Tenacetum Partheniunim (Feverfew) is probably
related to the inhibition of oxide nitric synthesis, to the
cytokines induction, to the release of serotonin from the
platelets and to the inhibition of the Calcitonin
Gene-Related Peptide (CGRP) release from the trigemi-
novascular system [11].
To this aim, keeping in mind all the above reported
considerations, we have performed a multicenter, pro-
spective study to evaluate the efficacy and safety of Par-
tena® tablets (a combination of Mg2+ 169 mg, CoQ10 20
mg, VitB2 4,8 mg, Feverfew 150mg-1,2 mg Parthenolides
and Andrographis paniculata 100 mg) available in Italy
as a dietary supplement (Italian Registry of Supplements
code 64289) in a population suffering from migraine/




This was a multicenter, prospective, observational study in
children and adolescents with migraine (with or without
aura) or tension-type headache. From January 2016 to De-
cember 2017, patients from 9 to 18 years were consecu-
tively enrolled from five different neurologic pediatric
centers in Italy (Sapienza University-Sant’Andrea Hospital,
Rome, Gaslini Childrens’ Hospital, Genoa, Sant’Orsola--
Malpighi Hospital, Bologna, “Businco Hospital”, Cagliari,
and University Hospital, Sassari). The study was con-
ducted in a context of routine practice without any add-
itional or unusual procedure of diagnosis or surveillance.
The study was also conducted according to the Declaration
of Helsinki. Written informed consent from a parent or
guardian and, when appropriate, child assent were obtained
prior to study partecipation. Patients underwent a baseline
evaluation performed by Pediatricians or Child Neurologists
with expertise in pediatric headache, in order to confirm the
diagnosis and their eligibility for the study. During the assess-
ment patients reported their age, medical history, migraine
family history, headache type and localization. Inclusion cri-
teria were migraine with aura (MA), without aura (MO) or
tension-type headache (TTH), as defined according to the
International Classification of Headache Disorders, 3rd
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Edition [12]. Moreover, a headache frequency of 4 or more
days/month should have been reported on a headache diary
over a pre-baseline period, for at least the latest 3 months.
Patients were excluded if they previously used headache
prophylactic treatment (drugs, nutritional supplement or
psychotherapy); all secondary headache disorders were also
excluded.
Partena® tablets, 1 tablet, twice a day, at regular interval,
was administered by Parents’ children, for the first 4
weeks, following by 12-weeks constant-dose phase of 1
tablet per day. Adherence and compliance to therapy and
side effects were recorded in the clinical headache diary,
during all phases of study. Patients were evaluated at base-
line (T0) at week 8 (T1) and at the end of treatment at
week 16 (T2). At week 20 (T3) and week 32 (T4), each en-
rolled patient was re-evaluated (follow-up period). Obvi-
ously, before entering the baseline phase, children had to
meet inclusion and exclusion criteria, as specified above.
Pain assessment
Patients completed a daily headache diary, in accordance
with the NINDS Common Data Elements [13]. A head-
ache day was defined as any day during which a head-
ache occurred within a 24-h period, starting at midnight.
The four-point pain scale (none, mild, moderate, severe)
has been used in this study to assess treatment efficacy.
Safety
Safety was assessed with the use of adverse-event reports
that were collected from parents and patients by means
of a structured interview.
Statistical analysis
A paired analysis of variance (ANOVA) and post-hoc
paired t-test analysis was performed to analyze compari-
son during treatment and follow-up period. Data were
given as mean ± standard deviation (SD). The two-sided
Fisher exact test was performed for contingency analysis.
Patients who did not maintain compliance to treatment
of at least 85% till the end of the study were considered
as censored data for the “pre-protocol” analysis. We ac-
cepted as significant p values of less than 0.05.
Results
A total of 91 patients (mean age 14.4 + 2.2; males 34%
and females 66%) were enrolled (demographic and clin-
ical variables at baseline are shown in Table 1.). Treat-
ment with Partena was substantially well tolerated, but
4.4% of patients interrupted the treatment due to gastro-
intestinal symptoms (nausea and diarrhea). A small
group of patients (8.8%) interrupted the study protocol
due to treatment inefficacy while the 7.7% of patients
was lost at follow-up.
In the intention-to-treat analysis (n= 91) the percentage of
patients showing a significant reduction of 50% or more in
the number of headache episodes at the end of the 16-weeks
treatment period (T2) was 50% in the TTH group, 55% in
the MO group and 85% in the MA group. A significant
maintenance of this effect after 16weeks from the treatment
withdrawal (T4), was seen for TTH (50%) and MO group
(53%), but not for MA patients which showed a slight but
significant reduction in the efficacy respect to the treatment
period (71%, p < 0.01 respect to T2).
The percentage of patients who completed the study was
75% of TTH, 83% of MO group and 100% of MA.
In the analysis per-protocol (n= 72), Partena significantly
reduced the frequency of headaches respect to baseline in
TTH patients (F(1.574, 22.04); p= 0.004) during the period
of treatment assumption (T0: 11.97 + 1.92 vs T2:
5.13 + 1.93; p < 0.001). The efficacy was maintained even
after 16weeks of treatment withdrawal (T4: 4.46 + 1.75; p <
0.001 respect to T0). A significant reduction of migraine fre-
quency was also found for MO group (F(2.740, 131.5); p <
0.0001) both during treatment (T0: 9.70 + 0.96 vs T2:
4.03 + 0.75; p < 0.01) and after 16weeks of treatment with-
drawal (T4: 2.96 + 0.65; p < 0.01 respect to T0). Conversely,
MA patients showed a significant effect in reducing head-
ache frequency during treatment (T0: 8.74 + 1.91 vs T2:
3.78 + 2.02; p < 0.01) but not until the end of the study (T4:
5.57 + 3.31; p > 0.05 respect to T0). (Fig. 1a).
In the assessment of pain intensity, TTH patients did
not show any significant amelioration (F (2.463, 34.49);
p > 0.05). Interestingly, a significant effect of treatment
was found in MO group (F(3.471, 166.6); p < 0.0001). In
particular, a reduction of pain intensity was found since 8
weeks of treatment (T0: 3.06 + 0.11 vs T1: 2.31 + 0.17; p
< 0.001), remain significant at 16 weeks (T2: 2.14 + 0.19; p
< 0.001 respect to T0) and at follow-up visits after treat-
ment withdrawal (T4: 2.20 + 0.21; p < 0.001 respect to
T0). Similarly MA group showed a significant treatment
effect (F(1.459, 8.752); p < 0.01) with a good response since
8 weeks of treatment (T0: 2.57 + 0.20 vs T1: 1.00 + 0.38; p
< 0.001), after 16 weeks (T2: 0.86 + 0.45; p < 0.001 respect
to T0) and the efficacy was maintained until the end of
the study (T4: 1.00 + 0.58; p < 0.001 respect to T0) (Fig.
1b). Globally, the reduction of pain intensity was higher,
Table 1 Demographic and clinical characteristics of patients at
baseline (n = 91)
Variable mean (± s.d.) or n (%)
Age, years 14,4 ± 2,2
Female 60 (66%)
Male 31 (34%)
Tension-type Headache (TTH) 20 (22%)
Migraine with aura (MA) 7 (8%)
Migraine without aura (MO) 64 (70%)
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although not significantly, among MA respect to MO pa-
tients when evaluated during treatment administration
(T2: 69% vs 29%; p = 0.12) and at the end of the study (T4:
67% vs 23%; p = 0.11).
Discussion
Our study showed that administration of Partena® for a
period of 16 treatment weeks reduced headache frequency
in a sample of children and adolescence affected by TTH
and Migraine. Moreover, in our observational study, treat-
ment with Partena was associated with lower intensity of
pain for migraine episodes among pediatric patients suffering
from MA and MO. We used a combination of magnesium,
riboflavin, CQ10, Tanacetum parthenium, molecules all aris-
ing in the guidelines of the American Headache Society
(AHS) and American Academy of Neurology (AAN) [14] in
addition to the Andrographis paniculata (plant extract that
has shown analgesic and anti-edema activity in preclinical
studies along with anti-nociceptive effects in an animal
model of sensory hypersensitivity associated with migraine)
[15]. Guidelines of the Società Italiana Studio Cefalee (SISC)
support the use of feverfew, Mg2+, riboflavin and CQ10 a
Level III recommendation [16].
Tanacetum parthenium (feverfew) has been used for
centuries to treat pain and headache [17]. Several pre-
clinical studies have identified different targets for
parthenolide like inhibition of platelet aggregation, in-
hibition of serotonin release from platelets and white
blood cells, reduction of iNOS (inducible nitric oxide
synthase) activation, inhibition of nuclear factor-kappaB
(a transcriptional factor involved in the mediation of
pain and inflammation) and binding to and inhibiting
IκB kinase complex (IKK) β that plays an important role
in proinflammatory cytokine-mediated signaling [18, 19].
More recent pharmacological data revealed that antimi-
graine effect of parthenolide may derives from its ability
to target transient receptor potential ankyrin 1 (TRPA1),
inducing nociceptor desensitization, ultimately resulting
in inhibition of Calcitonin gene-related peptide (CGRP)
release within the trigeminovascular system [20]. Clinical
evidences about the treatment of migraine are still
controversial although the contradictory results may
be attributed to the variations in the concentration
and to the differences in the stability of the partheno-
lides. The most recent randomized controlled trial,
using a stable feverfew extract, added some positive
evidences about the efficacy of parthenium in the
prophylactic treatment of migraine [17, 21]. Studies
on Feverfew efficacy in children and adolescents with
migraine are lacking [11].
The other active principles of Partena® currently avail-
able in Europe and USA as dietary supplements, have sev-
eral epidemiologic, preclinical and clinical evidences
supporting their usefulness in prophylactic treatment of
migraine [21]. Several studies revealed decreased levels of
the micronutrients riboflavin (Vit B2), magnesium (Mg)
Fig. 1 Results for frequency of attacks (a) and Intensity of pain (b) at baseline and at the post-baseline time points by subgroup of diagnosis
(values are means). Migraine with (MO) or without aura (MA), tension-type headache (TTH). Bars are standard deviations. *p < 0.05
Moscano et al. Italian Journal of Pediatrics           (2019) 45:36 Page 4 of 6
and CQ10 in plasma and brain of migraine patients [22].
On the other hand, numerous studies suggest a mitochon-
drial energy depletion in patients with migraine, and since all
these molecules play an important role in the production of
energy at mitochondrial level, multiple trials have assessed
their efficacy in migraine prevention [23–25]. Riboflavin is a
cofactor in oxidation-reduction reaction in the citric acid
cycle and the electron transport chain, as such it plays a key
role in the mitochondrial production of energy [21]. To date,
evidence in headache treatment for pediatric age gave dis-
cordant results [9, 10, 26]. CQ10 is a vitamin-like compound
needed for all cellular processes requiring energy. It is an
electron-carrier, transferring electrons from complex I/com-
plex II to cytochrome C in the mitochondrial electron trans-
port chain [27]. Preliminary evidences appear to support
efficacy for CQ10 in preventing migraines in children and
adolescents, but remain insufficient to make a strong conclu-
sion [26]. Mg2+ is necessary as a co-factor for proper func-
tioning of the ATP-synthase. Furthermore, Mg2+ is the
physiological antagonist at the NMDA-channel which is in-
volved in the regulation of neuronal excitability and inhib-
ition of cortical spreading depression (CSD) through several
mechanisms involving serotonin receptors, NO synthesis/re-
lease as well as NMDA receptors [28]. The role of magne-
sium in the prophylactic treatment of pediatric migraine is
still unclear and high-quality adequately powered trials are
needed [26]. Andrographolide has a broad range of pharma-
cological properties, mainly an anti-inflammatory effect, by
interfering with the production of inflammatory mediators,
in particular cyclooxygenase (COX) enzymes and
pro-inflammatory cytokines through the modulation of the
NF-κB signaling network and the NO/iNOS pathway [29].
Nevertheless, it is conceivable to suppose that administra-
tion of key micronutrients and phytoextracts able to inhibit
prostaglandin production and to interfere with the NO/iNOS
pathway as well as mitochondrial production of energy, might
prevent and/or reduce the number and intensity of the at-
tacks. This is more interesting when considering that treating
headaches in pediatric population is a continuous challenge
for clinicians. Although migraine in children is phenotypically
similar to adult migraine, medications efficacious in adults did
not show similar efficacy in pediatric controlled clinical trial
and none are currently FDA-approved for this age group [30,
31]. Therefore, it may be necessary to use medications off label
strictly weighing up the benefits and risks.
This study was performed on a small sample and the clin-
ical effects of nutraceutical have not been compared with
placebo. In fact, a limitation of our study is linked to the ab-
sence of a control group and on short time of observation.
Conclusions
To date there are scarce and contrasting evidences in favor
of the most utilized drugs for prophylactic therapy in
pediatric migraine and there are no significant differences
between the high placebo response rate and the low drug re-
sponse rate in pediatric age [9, 10]. Thus, the adult model of
headache treatment, in which, for example, amitriptyline and
topiramate, have been effective, may not apply to pediatric
patients. In addition, the reported serious adverse events in
children, do not show a favorable risk–benefit profile for the
use of these therapies in pediatric migraine prevention [9].
On the other hand, our result clearly indicates that Par-
tena® was able to reduce headaches frequency and pain in-
tensity in children and adolescences suffering from migraine
and TTH, therefore should be considered as a potential valu-
able prophylactic option for pediatric migraine. Although
this study remains mainly observational, clear indications on
the potential effectiveness, along with a favorable tolerability
profile, of this combination on pediatric headache/migraine
arose, and suggestion to perform further studies emerges to
confirm the trend observed here. Randomized controlled tri-
als are needed to further assess the effectiveness in nutraceu-
ticals’ use for migraine treatment in child and adolescent.
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